Curated News
By: NewsRamp Editorial Staff
April 30, 2026

HeartBeam to Discuss Q1 Results and Cardiac AI Advances on May 13

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • HeartBeam's upcoming conference call may reveal key updates on its limited commercial launch and AI programs, offering investors a competitive edge.
  • HeartBeam's 3D ECG technology, cleared by FDA for arrhythmia, synthesizes signals into 12-lead ECG for portable cardiac monitoring.
  • HeartBeam's cable-free device enables cardiac monitoring anywhere, improving access to care and potentially saving lives outside hospitals.
  • HeartBeam's 3D ECG collects signals from three directions, a novel approach to synthesize standard 12-lead ECG without cables.

Impact - Why it Matters

This news matters because HeartBeam's innovative 3D ECG technology could revolutionize how cardiac conditions are detected and monitored, enabling earlier intervention and reducing the need for hospital visits. For patients with heart disease, this means more convenient, accessible care that may lead to better health outcomes. Investors should also note the company's progress in commercializing its FDA-cleared devices, which could drive growth in the medtech sector.

Summary

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, has announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss its first-quarter results for the period ended March 31, 2026. The call will also provide updates on key growth initiatives, including the limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection, and AI programs. This development signals the company's progress in transforming cardiac health management through its groundbreaking platform technology.

HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This portable technology allows physicians to identify cardiac health trends and acute conditions outside of medical facilities, enabling timely intervention. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025. HeartBeam holds over 20 issued patents related to its technology enablement, underscoring its innovative edge in the medtech space.

Interested parties can view the full press release at https://ibn.fm/yN939 and stay updated with the latest news and updates relating to BEAT in the company’s newsroom at https://ibn.fm/BEAT. The company's forward-looking statements are subject to risks and uncertainties as detailed in its SEC filings. This announcement is particularly significant as HeartBeam advances its mission to redefine cardiac care, potentially improving outcomes for patients with heart conditions by providing actionable heart intelligence anytime, anywhere.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, HeartBeam to Discuss Q1 Results and Cardiac AI Advances on May 13

blockchain registration record for this content.